Vimarsana
Biggest News Aggregation in the World

Ellen Berlin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ellen Berlin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ellen Berlin Today - Breaking & Trending Today

Prestigious cancer research institute has retracted 7 studies amid controversy over errors - Vimarsana News

Prestigious cancer research institute has retracted 7 studies amid controversy over errors

Seven studies from researchers at the Dana-Farber Cancer Institute have been retracted, following allegations that images used in them had been manipulated or duplicated.

Source: yahoo.com
Endometrial, lung, and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2024 - Vimarsana News

Endometrial, lung, and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2024

Numerous studies conducted by researchers at Dana-Farber Cancer Institute show promising results for patients with endometrial, lung, breast, prostate, and colo

Endometrial, lung, and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2024 - Vimarsana News

Endometrial, lung, and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2024

Numerous studies conducted by researchers at Dana-Farber Cancer Institute show promising results for patients with endometrial, lung, breast, prostate, and colo

Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype - Vimarsana News

Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype

In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune

Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype - Vimarsana News

Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype

In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune